<DOC>
	<DOCNO>NCT03093740</DOCNO>
	<brief_summary>Open label single center study donation HCV positive kidney HCV negative recipient interventional treatment prevent HCV transmission upon transplantation .</brief_summary>
	<brief_title>Direct-acting Antiviral Therapy Prevent HCV Infection HCV Positive Donor HCV Negative Recipient Kidney Transplant</brief_title>
	<detailed_description>The study objective determine administration direct act antiviral 12-16 week kidney transplantation prevents spread HCV infection donor kidney know HCV infection ( genotype ) HCV negative recipient evidence negative HCV viral RNA 12 week post treatment .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Donor meet MGH transplant center criterion already list isolated kidney transplant No available live kidney donor Recipient ≤ 730 day accrue transplant wait time Recipient chronic hemodialysis peritoneal dialysis Recipient must agree birth control . °.Weigh ≥ 50kg Serum ALT within normal limit Subject 's Insurance company approve payment DAA therapy postkidney transplant AB Blood type HCV genotype 1 BMI &gt; 35 Any liver disease recipient Pregnant nursing ( lactate ) woman Known allergy intolerance tacrolimus would require administration cyclosporine Albumin &lt; 3g/dl Platelet count &lt; 75 x 103/mL Positive crossmatch positive donor specific antibody HCV RNA positive Hepatitis B surface antigen positive Patients primary focal segmental glomerulosclerosis ( FSGS ) Any contraindication kidney transplantation per center protocol</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>renal failure</keyword>
	<keyword>kidney transplant</keyword>
</DOC>